Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Appropriately aggregate holistic technologies via accurate expertise. Intrinsicly strategize worldwide initiatives and premium methodologies.

Blood-stage malaria vaccine candidate RH5.1/Matrix-M in healthy Tanzanian adults and children; an open-label, non-randomised, first-in-human, single-centre, phase 1b trial

Silk SE. et al, (2024), The Lancet Infectious Diseases, 24, 1105 - 1117

Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial.

Datoo MS. et al, (2024), Lancet (London, England), 403, 533 - 544

Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial

Datoo MS. et al, (2022), The Lancet Infectious Diseases, 22, 1728 - 1736

Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial

Datoo MS. et al, (2021), The Lancet, 397, 1809 - 1818

Safety and Immunogenicity of Adenovirus and Poxvirus Vectored Vaccines against a Mycobacterium Avium Complex Subspecies

Folegatti PM. et al, (2021), Vaccines, 9, 262 - 262

Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial.

Folegatti PM. et al, (2020), The Lancet. Infectious diseases, 20, 816 - 826

Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine

Folegatti PM. et al, (2019), Vaccines, 7, 40 - 40

Safety and Immunogenicity of a Heterologous Prime-Boost Ebola Virus Vaccine Regimen in Healthy Adults in the United Kingdom and Senegal

Venkatraman N. et al, (2019), The Journal of Infectious Diseases, 219, 1187 - 1197

Safety and Immunogenicity of the Heterosubtypic Influenza A Vaccine MVA-NP+M1 Manufactured on the AGE1.CR.pIX Avian Cell Line

Folegatti PM. et al, (2019), Vaccines, 7, 33 - 33

First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children

Tiono AB. et al, (2018), PLOS ONE, 13, e0208328 - e0208328

Assessment of novel vaccination regimens using viral vectored liver stage malaria vaccines encoding ME-TRAP

Bliss CM. et al, (2018), Scientific Reports, 8

Safety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAP

Rampling T. et al, (2018), npj Vaccines, 3

Prime and target immunization protects against liver-stage malaria in mice

Gola A. et al, (2018), Science Translational Medicine, 10, eaap9128 - eaap9128

Corrigendum to “Heterologous Two-dose Vaccination with Simian Adenovirus and Poxvirus Vectors Elicits Long-lasting Cellular Immunity to Influenza Virus A in Healthy Adults” [EBioMedicine 29 (2018) 146–154]

Coughlan L. et al, (2018), EBioMedicine, 31, 321 - 321

Heterologous Two-Dose Vaccination with Simian Adenovirus and Poxvirus Vectors Elicits Long-Lasting Cellular Immunity to Influenza Virus A in Healthy Adults

Coughlan L. et al, (2018), EBioMedicine, 29, 146 - 154

"PRIME-TARGET" IMMUNIZATION WITH VIRAL VECTORS FOR ENHANCED EFFICACY OF LIVER-STAGE MALARIA VACCINES

Ewer K. et al, (2018), AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 99, 585 - 585

Safety and Immunogenicity of Malaria Vectored Vaccines Given with Routine Expanded Program on Immunization Vaccines in Gambian Infants and Neonates: A Randomized Controlled Trial

Mensah VA. et al, (2017), Frontiers in Immunology, 8

Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactions

Payne RO. et al, (2017), JCI Insight, 2

IMMUNOGENICITY OF CHAD63/ MVA ME-TRAP MALARIA VECTORED VACCINE IS NOT AFFECTED BY CO-ADMINISTRATION WITH ROUTINE EPI VACCINES IN A RANDOMIZED CONTROLLED TRIAL IN GAMBIAN INFANTS AND NEONATES

Roetynck S. et al, (2017), AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 95, 193 - 193

SAFETY AND IMMUNOGENICITY OF THE NOVEL PLASMODIUM FALCIPARUM BLOOD-STAGE VACCINE CHAD63-MVA RH5 IN A PHASE IA CLINICAL TRIAL

Payne R. et al, (2017), AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 95, 313 - 313

Load More

Include forthcoming?